Clinical Trials

8 trials
RecentStart dateEnrollment
Recurrence × Bortezomib × Other hematologic neoplasm × Clear all
NCT00671112 2015-10-28

Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

Case Comprehensive Cancer Center

Phase 1 Terminated
30 enrolled
DermatologicLymphoidOther hematologic neoplasm

Subcutaneous panniculitis-like T-cell lymphoma, Immunoblastic Lymphadenopathy, Leukemia, Hairy Cell, Lymphoma, Lymphoma, Follicular, Waldenstrom Macroglobulinemia, Recurrence, Leukemia, Lymphocytic, Chronic, B-Cell, Leukemia, Prolymphocytic, T-Cell, Lymphoma, T-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Lymphoma, B-Cell, Marginal Zone, Lymphoma, Mantle-Cell, Leukemia, Large Granular Lymphocytic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma, Enteropathy-Associated T-Cell Lymphoma

NCT00383474 2015-04-15

Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase

National Cancer Institute (NCI)

Phase 1 Completed
35 enrolled
LymphoidOther hematologic neoplasm

Blast Crisis, Leukemia, Erythroblastic, Acute, Leukemia, Megakaryoblastic, Acute, Leukemia, Monocytic, Acute, Recurrence, Leukemia, Myeloid, Acute, Leukemia, Basophilic, Acute, Leukemia, Eosinophilic, Acute, Leukemia, Myelomonocytic, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma